Sarah Davis Posted Wednesday at 05:39 AM Posted Wednesday at 05:39 AM I'm in New Mexico and have been reading up on Korean plastic surgery options for later this year. Part of my planning is the pre-op side: I've been on a GLP-1 for weight loss, and my surgeon's coordinator mentioned that medications and general health get reviewed before anything is scheduled. That sent me down a rabbit hole, and I came across this news item about the FDA ordering a warning on a rare eye condition (NAION) linked to GLP-1 drugs: FDA orders GLP-1 warning over rare NAION eye condition https://viewtime.net/news/fda-glp1-warning-naion-eye-condition Now I'm second-guessing my timeline. I don't know how much of this actually matters for surgery clearance, or whether clinics in Korea ask about GLP-1 use at all during consultation. I'd rather bring it up myself than have it surface later, but I don't want to derail the conversation with something that turns out irrelevant to my situation. Has anyone here dealt with disclosing a GLP-1 prescription during pre-op consultations in Korea? How did the clinic handle it, and did it affect your scheduling? 1 Quote
LillyD86 Posted Wednesday at 02:45 PM Posted Wednesday at 02:45 PM South Korea knows a lot about GLP-1s and they give them out like candy over there. I have seen foreigners able to just walk into a clinic and get some, so they are well aware of the medication and what it does as well as side effects. I would imagine it should be brought up, but usually it is the responsibility of the patient to provide up-to-date medical history and drug use to the clinic. Quote
wishfulthinking23 Posted Thursday at 02:12 PM Posted Thursday at 02:12 PM Here is a summary of what is going on with this, it is all very new stuff : On November 9, 2026, the FDA mandated that all GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, carry a new warning regarding a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). This rare condition involves sudden, painless vision loss in one eye and can result in permanent blindness. Key details from the FDA’s assessment include: Incidence Rates: An analysis of 126 clinical trials found a NAION incidence of 6.4 cases per 100,000 patient-years among GLP-1 users, compared to 3.8 cases in comparator groups. Evidence: The FDA identified 15 probable NAION events across trials, with 10 occurring in patients taking GLP-1s, 5 in placebo recipients, and none in those taking other non-GLP-1 glucose-lowering medications. Clinical Guidance: Patients are advised to immediately report symptoms like sudden vision changes or blind spots to an ophthalmologist. Providers should consider discontinuing the GLP-1 if NAION is confirmed, unless benefits clearly outweigh risks. Screening: Experts state that routine eye exams specifically for NAION screening are not currently recommended for all users, as the absolute risk remains low and the causal mechanism is not fully established. ------------ Like Lilly said, it is best to let every doctor know if you are on any medication at all, especially for stuff like this where the medication is newer and they are still uncovering risk factors. I am not sure how this plays into surgery, recovery, or anything of that nature but this sounds like some scary stuff! Quote
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.